ACM
YMAB

ADAR1 Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

ADAR1 Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,045
Closed -$89K – 291
2023
Q4 		$89K Buy
+13,045
New +$75.5K 0.03% 99

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADAR1 Capital Management's YMAB Position: Q1 2024 in Review

ADAR1 Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2024, closing a stake of 13,045 shares — an estimated $89K sold.

ADAR1 Capital Management first reported a position in YMAB in Q4 2023 and held it in 1 quarter. The position peaked at $89K in Q4 2023. 96 funds tracked by Wall St. Rank hold YMAB as of Q1 2024.

  • ADAR1 Capital Management reported no remaining Y-mAbs Therapeutics position as of Q1 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 13,045 Y-mAbs Therapeutics shares in Q1 2024, an estimated $89K.
  • ADAR1 Capital Management first reported a position in Y-mAbs Therapeutics in Q4 2023 and held it in 1 quarter.
  • ADAR1 Capital Management's Y-mAbs Therapeutics position peaked at $89K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2024.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.